Management and grading of EGFR inhibitor-induced cutaneous toxicity

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

(2018) R -D Hofheinz et al.   ANNALS OF ONCOLOGY

Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

(2017) Jesper Grau Eriksen et al.   SUPPORTIVE CARE IN CANCER

Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies.

(2017) C. Kohne et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer

(2017) Barbara Burtness et al.   Journal of the National Comprehensive Cancer Network

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors

(2016) R.-D. Hofheinz et al.   ONCOLOGIST

Current targeted therapies in the treatment of advanced colorectal cancer: a review

(2016) Andrew Moriarity et al.   Therapeutic Advances in Medical Oncology

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

(2015) Yoshimitsu Kobayashi et al.   Future Oncology

Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors

(2014) Rod Sinclair   Asia-Pacific Journal of Clinical Oncology

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

(2014) Tanusree Paul et al.   EUROPEAN JOURNAL OF CANCER

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors

(2014) Paolo Lisi et al.   ONCOLOGY

Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

(2014) Florian Hohla   WORLD JOURNAL OF GASTROENTEROLOGY

The effects of treatment on itch in atopic dermatitis

(2013) Kevin B. Yarbrough et al.   Dermatologic Therapy

The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)

(2012) Lynne I. Wagner et al.   SUPPORTIVE CARE IN CANCER

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

(2012) Z. Reguiai et al.   SUPPORTIVE CARE IN CANCER

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors

(2012) Saurabh Ray et al.   JOURNAL OF MEDICAL ECONOMICS

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

(2011) Mario E. Lacouture et al.   SUPPORTIVE CARE IN CANCER

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

(2010) Alexandre Chan et al.   SUPPORTIVE CARE IN CANCER

Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy

(2009) R. E. Eilers et al.   JNCI-Journal of the National Cancer Institute

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes

(2008) Aminah Jatoi et al.   CANCER